Table 2.
COVID-19 clinical presentation and outcomes
| Common symptoms of COVID-19, N (%) | |
| Fever | 60 (68) |
| Fatigue | 48 (53) |
| Cough | 39 (44) |
| Dyspnea | 25 (28) |
| Complications of COVID-19, N (%) | |
| Pneumonia | 44 (61) |
| Respiratory failure | 10 (11) |
| Multiple organ failure | 8 (9) |
| Acute respiratory distress syndrome | 6 (7) |
| Pancreatitis | 2 (2) |
| Abnormal coagulation | 2 (2) |
| Anemia | 1 (1) |
| Frequency of ECOG performance status deterioration during COVID-19, % | 48 (55) |
| Course of COVID-19 | |
| Mild | 46 (52) |
| Noncritical care hospitalization | 14 (16) |
| Critical care hospitalization (oxygen support) | 12 (14) |
| Critical care hospitalization (mechanical ventilation) | 16 (18) |
| Duration of COVID-19, median (days) | 19.8 |
| Length of hospitalization, median (days) | 22.0 |
| Antiviral/COVID-19 therapy, N (%) | 42 (48) |
| Hydroxychloroquine | 31 (35) |
| Azithromycin | 17 (19) |
| Dexamethasone | 17 (19) |
| Favipiravir | 2 (2) |
| Ritonavir + Lopinavir | 1 (1) |
| COVID-19 disease outcome | |
| Convalescence, N (%) | 72 (82) |
| Death, N (%) | 16 (18) |
| 3-month overall survival, % | 82 |